- Home
- DFIN vs MLYS Comparison
DFIN vs MLYS Comparison
Compare DFIN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- MLYS
- Stock Information
- Founded
- DFIN 1983
- MLYS 2019
- Country
- DFIN United States
- MLYS United States
- Employees
- DFIN N/A
- MLYS N/A
- Industry
- DFIN Other Consumer Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- MLYS Health Care
- Exchange
- DFIN Nasdaq
- MLYS Nasdaq
- Market Cap
- DFIN 1.2B
- MLYS 1.0B
- IPO Year
- DFIN N/A
- MLYS 2023
- Fundamental
- Price
- DFIN $59.76
- MLYS $13.48
- Analyst Decision
- DFIN Strong Buy
- MLYS Strong Buy
- Analyst Count
- DFIN 3
- MLYS 4
- Target Price
- DFIN $68.67
- MLYS $27.00
- AVG Volume (30 Days)
- DFIN 222.2K
- MLYS 667.1K
- Earning Date
- DFIN 07-30-2025
- MLYS 08-12-2025
- Dividend Yield
- DFIN N/A
- MLYS N/A
- EPS Growth
- DFIN N/A
- MLYS N/A
- EPS
- DFIN 3.01
- MLYS N/A
- Revenue
- DFIN $779,600,000.00
- MLYS N/A
- Revenue This Year
- DFIN $1.99
- MLYS N/A
- Revenue Next Year
- DFIN $4.64
- MLYS N/A
- P/E Ratio
- DFIN $20.02
- MLYS N/A
- Revenue Growth
- DFIN N/A
- MLYS N/A
- 52 Week Low
- DFIN $37.80
- MLYS $8.24
- 52 Week High
- DFIN $71.01
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- DFIN 69.95
- MLYS 35.32
- Support Level
- DFIN $56.29
- MLYS $12.98
- Resistance Level
- DFIN $60.64
- MLYS $16.67
- Average True Range (ATR)
- DFIN 1.13
- MLYS 0.81
- MACD
- DFIN 0.13
- MLYS -0.33
- Stochastic Oscillator
- DFIN 87.99
- MLYS 13.56
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.